RPg Family Wealth Advisory LLC trimmed its stake in PRA Health Sciences Inc (NASDAQ:PRAH) by 5.6% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 15,713 shares of the medical research company’s stock after selling 939 shares during the quarter. RPg Family Wealth Advisory LLC’s holdings in PRA Health Sciences were worth $1,558,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Pearl River Capital LLC acquired a new stake in shares of PRA Health Sciences in the 2nd quarter worth about $40,000. Steward Partners Investment Advisory LLC bought a new stake in PRA Health Sciences in the 2nd quarter valued at about $49,000. Manchester Capital Management LLC bought a new position in PRA Health Sciences in the 1st quarter worth about $57,000. Advisor Group Inc. grew its position in PRA Health Sciences by 12.3% in the 2nd quarter. Advisor Group Inc. now owns 1,296 shares of the medical research company’s stock worth $129,000 after purchasing an additional 142 shares during the last quarter. Finally, Machina Capital S.A.S. acquired a new stake in shares of PRA Health Sciences in the second quarter valued at approximately $184,000. Institutional investors own 99.64% of the company’s stock.

A number of research firms have recently weighed in on PRAH. BidaskClub raised PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, July 24th. Jefferies Financial Group increased their price objective on PRA Health Sciences from $115.00 to $120.00 and gave the stock a “buy” rating in a report on Friday, September 6th. Svb Leerink restated a “market perform” rating on shares of PRA Health Sciences in a research report on Tuesday, July 2nd. Barclays lifted their target price on PRA Health Sciences from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th. Finally, Leerink Swann started coverage on PRA Health Sciences in a research note on Tuesday, July 2nd. They set a “market perform” rating and a $105.00 target price on the stock. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. PRA Health Sciences has an average rating of “Hold” and a consensus target price of $115.00.

In related news, major shareholder Fund Holdings L.P. Kkr sold 6,666,684 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $97.41, for a total transaction of $649,401,688.44. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.95% of the stock is owned by insiders.

Shares of PRAH stock traded up $1.54 during midday trading on Wednesday, reaching $101.98. 18,068 shares of the company were exchanged, compared to its average volume of 657,890. PRA Health Sciences Inc has a 12 month low of $82.12 and a 12 month high of $121.98. The company has a market cap of $6.59 billion, a P/E ratio of 25.75, a PEG ratio of 1.35 and a beta of 1.13. The company’s 50 day moving average price is $98.41 and its two-hundred day moving average price is $98.66. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.99 and a current ratio of 0.99.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings data on Wednesday, July 31st. The medical research company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.11 by $0.11. PRA Health Sciences had a net margin of 5.39% and a return on equity of 26.64%. The business had revenue of $763.31 million during the quarter, compared to analysts’ expectations of $764.95 million. During the same period last year, the firm posted $1.00 earnings per share. The business’s revenue was up 5.6% on a year-over-year basis. As a group, sell-side analysts predict that PRA Health Sciences Inc will post 4.63 earnings per share for the current year.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Read More: Why are analyst ratings important in trading stocks?

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.